PAVmed Revenue Jumps 513% in Q2
(NASDAQ:PAVM), a medical technology innovator focused on minimally invasive diagnostics and digital health devices, published its earnings results on August 14, 2025. The headline news was a notable outperformance: revenue (GAAP) reached $6.0 million, dramatically exceeding analyst GAAP expectations of $0.01 million. Non-GAAP earnings per share improved to $(0.11), ahead of the consensus estimate of $(0.13) (Non-GAAP). The quarter showed progress in revenue generation and cost management, despite a continued net loss, and reflects stabilization in key product lines and strategic partnerships.
Source: Analyst estimates for the quarter provided by FactSet.
PAVmed is a diversified life sciences company developing and commercializing innovative medical technologies. It operates through several subsidiaries, including Lucid Diagnostics and Veris Health. Lucid specializes in diagnostics, such as the EsoGuard DNA test for early detection of esophageal precancer, while Veris Health delivers a remote monitoring platform for cancer care. The company holds or licenses more than fifty patents worldwide across its diagnostic and health technology products.
Source Fool.com
